{"transactions":[{"id":741331,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:22.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001588861-26-000002","document":"form4-06112026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000158886126000002/form4-06112026_040605.xml","form_type":"4"}},{"id":1168252,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:08.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011108","document":"form4-04212025_050404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011108/form4-04212025_050404.xml","form_type":"4"}},{"id":1169518,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T22:50:11.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":8047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 60,000 shares of common stock of Legacy Tvardi with the exercise price of $0.63 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":8047,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":8047},"source":{"system":"sec-edgar","filing":"0001415889-25-010979","document":"form4-04172025_060407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010979/form4-04172025_060407.xml","form_type":"4"}},{"id":1169517,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T22:50:11.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":10394,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 77,500 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.09 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested and exercisable."}],"balance_after":10394,"derivative":{"exercise_price":0.68,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":10394},"source":{"system":"sec-edgar","filing":"0001415889-25-010979","document":"form4-04172025_060407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010979/form4-04172025_060407.xml","form_type":"4"}},{"id":1563823,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":357500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":357500},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563822,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563821,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":649999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":649999},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563820,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":284712,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":284712},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563819,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":536032,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":536032},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563818,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":314120,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":314120},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563817,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":146875},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563816,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":621101,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":9.21,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":621101},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563815,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.48,"expiration_date":"2027-04-26","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563814,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47916,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.72,"expiration_date":"2027-01-18","underlying":"Common Stock","underlying_shares":47916},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563813,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.82,"expiration_date":"2026-07-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563812,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.06,"expiration_date":"2026-01-25","underlying":"Common Stock","underlying_shares":39375},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563811,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":88351,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2025-01-06","underlying":"Common Stock","underlying_shares":88351},"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563810,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":96250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1563809,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:55:22.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":310420,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the \"Merger Agreement\"), by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-035447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035447/ownership.xml","form_type":"4"}},{"id":1575153,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":35799,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575152,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":2288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2021."}],"balance_after":12845,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":2288},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575151,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":22076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48 of the underlying shares monthly from January 31, 2020."}],"balance_after":0,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":22076},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575150,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":14372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":14372},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575149,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575148,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":18899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 1/48 of the underlying shares monthly from October 27, 2017."}],"balance_after":0,"derivative":{"exercise_price":9.21,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":18899},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575147,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":52084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on the first anniversary of the grant date, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.72,"expiration_date":"2027-01-18","underlying":"Common Stock","underlying_shares":52084},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575146,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":14625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on the first anniversary of the grant date, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.06,"expiration_date":"2026-01-25","underlying":"Common Stock","underlying_shares":14625},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575145,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":false,"shares":11649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on the first anniversary of the grant date, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2025-01-06","underlying":"Common Stock","underlying_shares":11649},"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575144,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":1,"price":2.94,"value":2.94,"ownership":{"direct":true},"balance_after":406670,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575143,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":2288,"price":5.78,"value":13224.64,"ownership":{"direct":true},"balance_after":406669,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575142,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":22076,"price":4.05,"value":89407.8,"ownership":{"direct":true},"balance_after":404381,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575141,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":14372,"price":8.43,"value":121155.96,"ownership":{"direct":true},"balance_after":382305,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575140,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":3125,"price":11.69,"value":36531.25,"ownership":{"direct":true},"balance_after":367933,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575139,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":18899,"price":9.21,"value":174059.79,"ownership":{"direct":true},"balance_after":364808,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575138,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":52084,"price":1.72,"value":89584.48,"ownership":{"direct":true},"balance_after":345909,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575137,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":14625,"price":1.06,"value":15502.5,"ownership":{"direct":true},"balance_after":293825,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1575136,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-15T16:03:54.000Z","date":"2024-03-13","kind":"exercise","planned":false,"acquired":true,"shares":11649,"price":10,"value":116490.0,"ownership":{"direct":true},"balance_after":279200,"source":{"system":"sec-edgar","filing":"0001062993-24-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324006513/form4.xml","form_type":"4"}},{"id":1669904,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-26T18:27:47.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":357500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2024."}],"balance_after":357500,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":357500},"source":{"system":"sec-edgar","filing":"0001062993-24-001426","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001426/form4.xml","form_type":"4"}},{"id":1669903,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-26T18:27:47.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":96250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant shall vest as to 1/4 of the shares on each of January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028."}],"balance_after":267551,"source":{"system":"sec-edgar","filing":"0001062993-24-001426","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001426/form4.xml","form_type":"4"}},{"id":1716692,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":false,"shares":20856,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2024-01-05","underlying":"Common Stock","underlying_shares":20856},"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1716691,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Right","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":false,"shares":12973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":12973},"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1716690,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":false,"shares":31036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":31036},"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1716689,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"sale","planned":true,"acquired":false,"shares":890,"price":20.81,"value":18520.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023."}],"balance_after":171301,"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1716688,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":true,"shares":890,"price":5,"value":4450.0,"ownership":{"direct":true},"balance_after":172191,"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1716687,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"sale","planned":true,"acquired":false,"shares":63975,"price":19.9867,"value":1278649.1325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.56, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":171301,"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1716686,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-11T19:03:17.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":true,"shares":63975,"price":5,"value":319875.0,"ownership":{"direct":true},"balance_after":235276,"source":{"system":"sec-edgar","filing":"0001062993-23-022368","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323022368/form4.xml","form_type":"4"}},{"id":1742744,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":false,"shares":20855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months."}],"balance_after":20856,"derivative":{"exercise_price":5,"expiration_date":"2024-01-05","underlying":"Common Stock","underlying_shares":20855},"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1742743,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Right","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":false,"shares":12972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date."}],"balance_after":12973,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":12972},"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1742742,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":false,"shares":31036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter."}],"balance_after":31036,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":31036},"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1742741,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"sale","planned":true,"acquired":false,"shares":20855,"price":15.8883,"value":331350.4965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $16.28, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":171301,"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1742740,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":true,"shares":20855,"price":5,"value":104275.0,"ownership":{"direct":true},"balance_after":192156,"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1742739,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"sale","planned":true,"acquired":false,"shares":44008,"price":15.8905,"value":699309.124,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $16.28, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":171301,"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1742738,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-14T18:00:13.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":true,"shares":44008,"price":5,"value":220040.0,"ownership":{"direct":true},"balance_after":215309,"source":{"system":"sec-edgar","filing":"0001062993-23-020835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323020835/form4.xml","form_type":"4"}},{"id":1762877,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-10T17:04:11.000Z","date":"2023-10-09","kind":"exercise","planned":true,"acquired":false,"shares":20855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months."}],"balance_after":41711,"derivative":{"exercise_price":5,"expiration_date":"2024-01-05","underlying":"Common Stock","underlying_shares":20855},"source":{"system":"sec-edgar","filing":"0001062993-23-019205","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019205/form4.xml","form_type":"4"}},{"id":1762876,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Right","published_at":"2023-10-10T17:04:11.000Z","date":"2023-10-09","kind":"exercise","planned":true,"acquired":false,"shares":12972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date."}],"balance_after":25945,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":12972},"source":{"system":"sec-edgar","filing":"0001062993-23-019205","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019205/form4.xml","form_type":"4"}},{"id":1762875,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-10T17:04:11.000Z","date":"2023-10-09","kind":"exercise","planned":true,"acquired":false,"shares":31034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter."}],"balance_after":62072,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":31034},"source":{"system":"sec-edgar","filing":"0001062993-23-019205","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019205/form4.xml","form_type":"4"}},{"id":1762874,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-10T17:04:11.000Z","date":"2023-10-09","kind":"sale","planned":true,"acquired":false,"shares":64861,"price":14.204,"value":921285.644,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.07 to $14.35, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":171301,"source":{"system":"sec-edgar","filing":"0001062993-23-019205","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019205/form4.xml","form_type":"4"}},{"id":1762873,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-10T17:04:11.000Z","date":"2023-10-09","kind":"exercise","planned":true,"acquired":true,"shares":64861,"price":5,"value":324305.0,"ownership":{"direct":true},"balance_after":236162,"source":{"system":"sec-edgar","filing":"0001062993-23-019205","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323019205/form4.xml","form_type":"4"}},{"id":2043969,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-27T16:27:41.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2023."}],"balance_after":800000,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001062993-23-001493","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323001493/form4.xml","form_type":"4"}},{"id":2240581,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-07T08:14:18.000Z","date":"2022-06-06","kind":"purchase","acquired":true,"shares":51301,"price":1.95,"value":100036.95,"ownership":{"direct":true},"balance_after":171301,"source":{"system":"sec-edgar","filing":"0001062993-22-014432","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322014432/form4.xml","form_type":"4"}},{"id":2424289,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-27T16:55:10.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2022."}],"balance_after":650000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001062993-22-001697","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322001697/form4.xml","form_type":"4"}},{"id":2892494,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-28T14:56:35.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":287000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48 of the underlying shares monthly from January 1, 2021."}],"balance_after":287000,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":287000},"source":{"system":"sec-edgar","filing":"0001333277-21-000020","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327721000020/edgar.xml","form_type":"4"}},{"id":3143409,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-19T17:12:47.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":558108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 48 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date."}],"balance_after":558108,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":558108},"source":{"system":"sec-edgar","filing":"0001209191-20-030579","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919120030579/doc4.xml","form_type":"4"}},{"id":3393822,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-10-15T08:20:50.000Z","date":"2019-10-10","kind":"purchase","acquired":true,"shares":5000,"price":4.3,"value":21500.0,"ownership":{"direct":true},"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001333277-19-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000046/edgar.xml","form_type":"4"}},{"id":3407210,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-09-24T08:56:10.000Z","date":"2019-09-23","kind":"purchase","acquired":true,"shares":3100,"price":5.55,"value":17205.0,"ownership":{"direct":true},"balance_after":115000,"source":{"system":"sec-edgar","filing":"0001333277-19-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000044/edgar.xml","form_type":"4"}},{"id":3407209,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-09-24T08:56:10.000Z","date":"2019-09-20","kind":"purchase","acquired":true,"shares":1900,"price":5.5,"value":10450.0,"ownership":{"direct":true},"balance_after":111900,"source":{"system":"sec-edgar","filing":"0001333277-19-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000044/edgar.xml","form_type":"4"}},{"id":3681495,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-31T17:26:59.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":328492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":328492,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":328492},"source":{"system":"sec-edgar","filing":"0001333277-19-000026","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000026/edgar.xml","form_type":"4"}},{"id":3722214,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-21T17:11:25.000Z","date":"2018-12-21","kind":"purchase","acquired":true,"shares":10000,"price":6.5399,"value":65399.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  The shares were purchased in multiple transactions at prices ranging from $6.5397 to $6.54, inclusive.  The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001333277-18-000041","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000041/edgar.xml","form_type":"4"}},{"id":3790041,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-16T06:21:13.000Z","date":"2018-10-15","kind":"purchase","acquired":true,"shares":5000,"price":9.9,"value":49500.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001333277-18-000040","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000040/edgar.xml","form_type":"4"}},{"id":3859226,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-07-30T06:05:53.000Z","date":"2018-07-27","kind":"purchase","acquired":true,"shares":5000,"price":10.9,"value":54500.0,"ownership":{"direct":true},"balance_after":95000,"source":{"system":"sec-edgar","filing":"0001333277-18-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000037/edgar.xml","form_type":"4"}},{"id":3933328,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-05-15T08:08:52.000Z","date":"2018-05-11","kind":"purchase","acquired":true,"shares":5000,"price":10.65,"value":53250.0,"ownership":{"direct":true},"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001333277-18-000036","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000036/edgar.xml","form_type":"4"}},{"id":4088451,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-26T17:41:41.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":150000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001333277-18-000030","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000030/edgar.xml","form_type":"4"}},{"id":4177688,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-10-31T21:31:20.000Z","date":"2017-10-27","kind":"grant","acquired":true,"shares":640000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 48 equal monthly installments commencing on October 27, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date."}],"balance_after":640000,"derivative":{"exercise_price":9.21,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":640000},"source":{"system":"sec-edgar","filing":"0001209191-17-058527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117058527/doc4.xml","form_type":"4"}},{"id":4252698,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2017-07-24T06:15:13.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":8033,"price":7.35,"value":59042.55,"ownership":{"direct":true},"balance_after":85000,"source":{"system":"sec-edgar","filing":"0001209191-17-046040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117046040/doc4.xml","form_type":"4"}},{"id":4252697,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2017-07-24T06:15:13.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":100,"price":7.32,"value":732.0,"ownership":{"direct":true},"balance_after":76967,"source":{"system":"sec-edgar","filing":"0001209191-17-046040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117046040/doc4.xml","form_type":"4"}},{"id":4252696,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2017-07-24T06:15:13.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":576,"price":7.31,"value":4210.56,"ownership":{"direct":true},"balance_after":76867,"source":{"system":"sec-edgar","filing":"0001209191-17-046040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117046040/doc4.xml","form_type":"4"}},{"id":4252695,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2017-07-24T06:15:13.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":400,"price":7.3,"value":2920.0,"ownership":{"direct":true},"balance_after":76291,"source":{"system":"sec-edgar","filing":"0001209191-17-046040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117046040/doc4.xml","form_type":"4"}},{"id":4252694,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2017-07-24T06:15:13.000Z","date":"2017-07-20","kind":"purchase","acquired":true,"shares":891,"price":7.29,"value":6495.39,"ownership":{"direct":true},"balance_after":75891,"source":{"system":"sec-edgar","filing":"0001209191-17-046040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117046040/doc4.xml","form_type":"4"}},{"id":4340614,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-05-01T19:47:18.000Z","date":"2017-04-27","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over the eight-month period beginning on the vesting commencement date of April 15, 2017, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":90000,"derivative":{"exercise_price":3.48,"expiration_date":"2027-04-26","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001179110-17-006329","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017006329/edgar.xml","form_type":"4"}},{"id":4484248,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-23T18:29:08.000Z","date":"2017-01-19","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years."}],"balance_after":100000,"derivative":{"exercise_price":1.72,"expiration_date":"2027-01-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-17-001190","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017001190/edgar.xml","form_type":"4"}},{"id":4496702,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-06T19:31:30.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 25, 2016, the Reporting Person was granted an option to purchase 50,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met on December 30, 2016, resulting in vesting of the option as to 25,000 shares, which was reported on a prior Form 4.  The second milestone was met on January 4, 2017, resulting in vesting of the option as to the remaining 25,000 shares."}],"balance_after":50000,"derivative":{"exercise_price":1.82,"exercise_date":"2017-01-04","expiration_date":"2026-07-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-17-000724","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017000724/edgar.xml","form_type":"4"}},{"id":4503677,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":39186,"kind":"person","name":"Shah Sujal","position":1,"cik":"0001588861","reported_name":"Shah Sujal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-04T20:18:35.000Z","date":"2016-12-30","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 25, 2016, the Reporting Person was granted an option to purchase 50,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met, resulting in vesting of the option as to 25,000 shares."}],"balance_after":25000,"derivative":{"exercise_price":1.82,"exercise_date":"2016-12-30","expiration_date":"2026-07-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-17-000410","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017000410/edgar.xml","form_type":"4"}}]}